SUPPLEMENT
Q4 2022 — Financial disclosures
Q4 2022PDF · 10 pages1.0 MB
Merck & Co., Inc. Financial Highlights Package Fourth Quarter 2022 Table of Contents Table 1: GAAP P&L.....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter..................2 Table 2a: GAAP to Non-GAAP Reconciliation 4Q22 and Dec YTD 22.........3 Table 2b: GAAP to Non-GAAP Reconciliation 4Q21 and Dec YTD 21.........4 Table 3: Sales - Current Year and Prior Year by Quarter...........................5 Table 3a: Sales – U.S. / Ex- U.S. 4Q22........................................................6 Table 3b: Sales – U.S. / Ex- U.S. Dec YTD 22............................................7 Table 3c: Sales – Pharmaceutical Geographic Split....................................8 Table 4: Other (Income) Expense .............................................................9 -- 1 of 10 -- Sales 13,830 $ 13,521 $ 2% 59,283 $ 48,704 $ 22% Costs, Expenses and Other Cost of sales 3,881 3,873 0% 17,411 13,626 28% Selling, general and administrative 2,687 2,830 -5% 10,042 9,634 4% Research and development 3,775 3,068 23% 13,548 12,245 11% Restructuring costs 49 174 -72% 337 661 -49% Other (income) expense, net (75) (333) -77% 1,501 (1,341) * Income from Continuing Operations Before Taxes 3,513 3,909 -10% 16,444 13,879 18% Income Tax Provision 495 85 1,918 1,521 Net Income from Continuing Operations 3,018 3,824 -21% 14,526 12,358 18% Less: Net Income Attributable to Noncontrolling Interests 1 4 7 13 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,017 3,820 -21% 14,519 12,345 18% (Loss) Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests - (62) * - 704 * Net Income Attributable to Merck & Co., Inc. 3,017 $ 3,758 $ -20% 14,519 $ 13,049 $ 11% Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.19 $ 1.51 $ -21% 5.73 $ 4.88 $ 17% (Loss) Income from Discontinued Operations - (0.02) * - 0.28 * Net Income 1.19 $ 1.49 $ -20% 5.73 $ 5.16 $ 11% Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.18 $ 1.51 $ -22% 5.71 $ 4.86 $ 17% (Loss) Income from Discontinued Operations - (0.02) * - 0.28 * Net Income 1.18 $ 1.48 $ -20% 5.71 $ 5.14 $ 11% Average Shares Outstanding 2,536 2,527 2,532 2,530 Average Shares Outstanding Assuming Dilution 2,548 2,535 2,542 2,538 Tax Rate from Continuing Operations 14.1% 2.2% 11.7% 11.0% * 100% or greater Full Year 2021 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 On June 2, 2021, Merck completed the spinoff of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon). The historical results of the businesses that were contributed to Organon in the spin-off are excluded from sales and expenses below and reflected as discontinued operations in the company’s Consolidated Statements of Income provided below. 4Q21 GAAP % Change GAAP % Change 4Q22 Full Year 2022 1 -- 2 of 10 -- Sales 15,901 $ 14,593 $ 14,959 $ 13,830 $ 59,283 $ 10,627 $ 11,402 $ 13,154 $ 13,521 $ 48,704 $ 2% 22% Costs, Expenses and Other Cost of sales 5,380 4,216 3,934 3,881 17,411 3,199 3,104 3,450 3,873 13,626 0% 28% Selling, general and administrative 2,323 2,512 2,520 2,687 10,042 2,187 2,281 2,336 2,830 9,634 -5% 4% Research and development 2,576 2,798 4,399 3,775 13,548 2,412 4,321 2,445 3,068 12,245 23% 11% Restructuring costs 53 142 94 49 337 297 82 107 174 661 -72% -49% Other (income) expense, net 708 438 429 (75) 1,501 (455) (103) (450) (333) (1,341) -77% * Income from Continuing Operations Before Taxes 4,861 4,487 3,583 3,513 16,444 2,987 1,717 5,266 3,909 13,879 -10% 18% Income Tax Provision 554 538 330 495 1,918 238 503 695 85 1,521 Net Income from Continuing Operations 4,307 3,949 3,253 3,018 14,526 2,749 1,214 4,571 3,824 12,358 -21% 18% Less: Net (Loss) Income Attributable to Noncontrolling Interests (3) 5 5 1 7 4 1 4 4 13 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,310 3,944 3,248 3,017 14,519 2,745 1,213 4,567 3,820 12,345 -21% 18% Income (Loss) from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests - - - - - 434 332 - (62) 704 * * Net Income Attributable to Merck & Co., Inc. 4,310 $ 3,944 $ 3,248 $ 3,017 $ 14,519 $ 3,179 $ 1,545 $ 4,567 $ 3,758 $ 13,049 $ -20% 11% Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.70 $ 1.56 $ 1.28 $ 1.19 $ 5.73 $ 1.08 $ 0.48 $ 1.81 $ 1.51 $ 4.88 $ -21% 17% Income (Loss) from Discontinued Operations - - - - - 0.17 0.13 - (0.02) 0.28 * * Net Income 1.70 $ 1.56 $ 1.28 $ 1.19 $ 5.73 $ 1.26 $ 0.61 $ 1.81 $ 1.49 $ 5.16 $ -20% 11% Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.70 $ 1.55 $ 1.28 $ 1.18 $ 5.71 $ 1.08 $ 0.48 $ 1.80 $ 1.51 $ 4.86 $ -22% 17% Income (Loss) from Discontinued Operations - - - - - 0.17 0.13 - (0.02) 0.28 * * Net Income 1.70 $ 1.55 $ 1.28 $ 1.18 $ 5.71 $ 1.25 $ 0.61 $ 1.80 $ 1.48 $ 5.14 $ -20% 11% Average Shares Outstanding 2,528 2,531 2,533 2,536 2,532 2,531 2,533 2,530 2,527 2,530 Average Shares Outstanding Assuming Dilution 2,537 2,540 2,542 2,548 2,542 2,541 2,540 2,536 2,535 2,538 Tax Rate from Continuing Operations 11.4% 12.0% 9.2% 14.1% 11.7% 8.0% 29.3% 13.2% 2.2% 11.0% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) 2022 2Q 3Q 4Q Full Year 1Q 1Q 2Q 3Q 4Q Full Year 2021 % Change 4Q Full Year 2 -- 3 of 10 -- Fourth Quarter Cost of sales 3,881 $ 482 38 520 3,361 $ Selling, general and administrative 2,687 39 20 59 2,628 Research and development 3,775 740 740 3,035 Restructuring costs 49 49 49 - Other (income) expense, net (75) (69) 80 11 (86) Income from Continuing Operations Before Taxes 3,513 (1,192) (107) (80) (1,379) 4,892 Income Tax Provision (Benefit) 495 (222) (3) (32) (3) (13) (3) (267) 762 Net Income from Continuing Operations 3,018 (970) (75) (67) (1,112) 4,130 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,017 (970) (75) (67) (1,112) 4,129 Earnings per Common Share Assuming Dilution from Continuing Operations 1.18 $ (0.38) (0.03) (0.03) (0.44) 1.62 $ Tax Rate 14.1% 15.6% Full Year Cost of sales 17,411 $ 2,059 205 2,264 15,147 $ Selling, general and administrative 10,042 176 94 270 9,772 Research and development 13,548 1,676 30 1,706 11,842 Restructuring costs 337 337 337 - Other (income) expense, net 1,501 (207) 1,348 1,141 360 Income from Continuing Operations Before Taxes 16,444 (3,704) (666) (1,348) (5,718) 22,162 Income Tax Provision (Benefit) 1,918 (809) (3) (129) (3) (294) (3) (1,232) 3,150 Net Income from Continuing Operations 14,526 (2,895) (537) (1,054) (4,486) 19,012 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 14,519 (2,895) (537) (1,054) (4,486) 19,005 Earnings per Common Share Assuming Dilution from Continuing Operations 5.71 $ (1.14) (0.21) (0.42) (1.77) 7.48 $ Tax Rate 11.7% 14.2% Only the line items that are affected by non-GAAP adjustments are shown. MERCK & CO., INC. FOURTH QUARTER AND FULL YEAR 2022 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Table 2a Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses for the fourth quarter and full year primarily reflect $780 million and $1.7 billion, respectively, of intangible asset impairment charges largely related to nemtabrutinib, which was obtained as part of the 2020 ArQule, Inc. acquisition, and expenses for the amortization of intangible assets, partially offset by a reduction in expenses related to changes in the estimated fair value of liabilities for contingent consideration. Amounts included in other (income) expense, net, for the fourth quarter and full year reflect royalty income and decreases in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Adjustment Subtotal Non-GAAP 3 -- 4 of 10 -- Fourth Quarter Cost of sales 3,873 $ 419 47 (4) 462 3,411 $ Selling, general and administrative 2,830 226 10 236 2,594 Research and development 3,068 397 7 404 2,664 Restructuring costs 174 174 174 - Other (income) expense, net (333) (3) (381) (384) 51 Income from Continuing Operations Before Taxes 3,909 (1,039) (238) 381 4 (892) 4,801 Income Tax Provision (Benefit) 85 (163) (4) (39) (4) 84 (4) (2) (4) (120) 205 Net Income from Continuing Operations 3,824 (876) (199) 297 6 (772) 4,596 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,820 (876) (199) 297 6 (772) 4,592 Earnings per Common Share Assuming Dilution from Continuing Operations 1.51 $ (0.34) (0.08) 0.12 - (0.30) 1.81 $ Tax Rate 2.2% 4.3% Full Year Cost of sales 13,626 $ 1,607 160 221 (3) 1,988 11,638 $ Selling, general and administrative 9,634 322 19 341 9,293 Research and development 12,245 479 28 507 11,738 Restructuring costs 661 661 661 - Other (income) expense, net (1,341) 76 (1,884) (1,808) 467 Income from Continuing Operations Before Taxes 13,879 (2,484) (868) 1,884 (221) (1,689) 15,568 Income Tax Provision (Benefit) 1,521 (446) (4) (121) (4) 415 (4) (259) (4) (411) 1,932 Net Income from Continuing Operations 12,358 (2,038) (747) 1,469 38 (1,278) 13,636 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 12,345 (2,038) (747) 1,469 38 (1,278) 13,623 Earnings per Common Share Assuming Dilution from Continuing Operations 4.86 $ (0.80) (0.30) 0.58 0.01 (0.51) 5.37 $ Tax Rate 11.0% 12.4% Only the line items that are affected by non-GAAP adjustments are shown. MERCK & CO., INC. FOURTH QUARTER AND FULL YEAR 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b (4) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the full year also includes a $207 million net tax benefit related to the settlement of certain federal income tax matters. In 2022, the company changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the charges were considered by the company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Beginning in 2022, Merck’s non-GAAP results no longer exclude charges related to these items. Results for 2021 have been recast to conform to the new presentation. Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non- GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures, including $169 million of transaction costs related to the acquisition of Acceleron Pharma Inc. (Acceleron) in 2021. Amounts included in research and development expenses primarily reflect a $275 million in-process research and development (IPR&D) impairment charge related to nemtabrutinib, which was obtained as part of the 2020 ArQule, Inc. acquisition, $105 million of Acceleron transaction costs, and expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, reflect increases in the estimated fair value measurement of liabilities for contingent consideration and royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture. Additionally, the full year includes a loss on a forward exchange contract entered into in conjunction with the Organon spin-off. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Reflects charges for the discontinuation of COVID-19 development programs. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Adjustment Subtotal The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below. 4 -- 5 of 10 -- 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $15,901 $14,593 $14,959 $13,830 $59,283 $10,627 $11,402 $13,154 $13,521 $48,704 2 8 22 26 PHARMACEUTICAL 14,107 12,756 12,963 12,180 52,005 9,238 9,980 11,496 12,039 42,754 1 9 22 28 Oncology Keytruda 4,809 5,252 5,426 5,450 20,937 3,899 4,176 4,534 4,577 17,186 19 26 22 27 Alliance Revenue – Lynparza (2) 266 275 284 292 1,116 228 248 246 268 989 9 14 13 18 Alliance Revenue – Lenvima (2) 227 231 202 216 876 130 181 188 206 704 5 9 24 28 Alliance Revenue – Reblozyl (3) 52 33 39 41 166 17 17 145 145 * * Vaccines (4) Gardasil / Gardasil 9 1,460 1,674 2,294 1,470 6,897 917 1,234 1,993 1,528 5,673 -4 6 22 27 ProQuad / M-M-R II / Varivax 470 578 668 526 2,241 449 516 661 509 2,135 3 6 5 7 RotaTeq 216 173 256 139 783 158 208 227 213 807 -35 -31 -3 0 Pneumovax 23 173 153 131 145 602 171 152 277 292 893 -50 -47 -33 -30 Vaqta 36 35 64 39 173 34 56 48 41 179 -5 -2 -3 -2 Hospital Acute Care Bridion 395 426 423 441 1,685 340 387 369 436 1,532 1 7 10 16 Prevymis 94 103 114 118 428 82 93 96 100 370 17 28 16 24 Dificid 52 66 77 67 263 27 34 54 60 175 12 12 50 50 Primaxin 58 64 63 54 239 65 60 70 65 259 -17 -7 -8 -4 Noxafil 57 60 62 58 238 67 66 64 62 259 -5 7 -8 -1 Invanz 52 46 50 40 189 57 48 53 45 202 -10 -2 -7 -1 Cancidas 53 42 43 36 174 57 54 56 45 212 -19 -10 -18 -14 Zerbaxa 30 46 43 49 169 (8) (1) (2) 10 (1) * * * * Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 72 98 88 82 341 74 74 100 94 342 -12 -12 - - Adempas (6) 61 63 57 57 238 55 74 59 63 252 -10 6 -6 7 Virology Lagevrio 3,247 1,177 436 825 5,684 952 952 -13 2 * * Isentress / Isentress HD 158 147 161 167 633 209 192 189 178 769 -7 -1 -18 -13 Neuroscience Belsomra 69 69 62 59 258 79 78 81 80 318 -27 -14 -19 -9 Immunology Simponi 186 181 173 166 706 214 202 203 206 825 -19 -8 -14 -4 Remicade 61 53 49 44 207 85 75 73 67 299 -34 -22 -31 -21 Diabetes (7) Januvia 779 756 717 561 2,813 809 784 852 878 3,324 -36 -31 -15 -11 Janumet 454 476 417 353 1,700 486 477 487 514 1,964 -31 -25 -13 -7 Other Pharmaceutical (8) 520 479 564 685 2,249 554 512 518 533 2,118 29 37 6 12 ANIMAL HEALTH 1,482 1,467 1,371 1,230 5,550 1,418 1,472 1,417 1,261 5,568 -2 6 - 6 Livestock 832 826 829 814 3,300 819 821 864 791 3,295 3 12 - 7 Companion Animals 650 641 542 416 2,250 599 651 553 470 2,273 -11 -5 -1 4 Other Revenues (9) 312 370 625 420 1,728 (29) (50) 241 221 382 90 -25 * 87 * 200% or greater 2022 2021 4Q Full Year MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $1,305 million, $1,300 million, $1,231 million and $1,012 million in the first, second, third quarter and fourth quarter of 2022, respectively, and $1,363 million, $1,330 million, $1,417 million and $1,475 million in the first, second, third and fourth quarter of 2021, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $114 million, $32 million, $10 million and $10 million in the first, second, third and fourth quarter of 2022, respectively, and $56 million, $135 million and $27 million in the first, third and fourth quarter of 2021, respectively. Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment. (4) Total Vaccines sales were $2,481 million, $2,709 million, $3,552 million and $2,554 million in the first, second, third and fourth quarter of 2022, respectively, and $1,809 million, $2,293 million, $3,315 million and $2,715 million in the first, second, third and fourth quarter of 2021, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 5 -- 6 of 10 -- 4Q 2022 4Q 2021 % Change 4Q 2022 4Q 2021 % Change 4Q 2022 4Q 2021 % Change TOTAL SALES (1) $13,830 $13,521 2 $6,279 $6,259 - $7,551 $7,262 4 PHARMACEUTICAL 12,180 12,039 1 5,871 5,790 1 6,309 6,249 1 Oncology Keytruda 5,450 4,577 19 3,378 2,657 27 2,071 1,920 8 Alliance Revenue - Lynparza (2) 292 268 9 157 144 9 135 123 9 Alliance Revenue - Lenvima (2) 216 206 5 154 131 18 62 75 -18 Alliance Revenue - Reblozyl (3) 41 17 145 36 100 6 17 -66 Vaccines (4) Gardasil / Gardasil 9 1,470 1,528 -4 262 275 -5 1,207 1,253 -4 ProQuad / M-M-R II / Varivax 526 509 3 387 374 4 139 135 3 Pneumovax 23 145 292 -50 66 193 -66 79 99 -20 RotaTeq 139 213 -35 82 109 -25 57 105 -46 Vaqta 39 41 -5 23 20 14 16 21 -24 Hospital Acute Care Bridion 441 436 1 257 218 18 183 218 -16 Prevymis 118 100 17 52 42 25 65 58 12 Dificid 67 60 12 57 57 -1 10 3 * Noxafil 58 62 -5 13 11 11 46 50 -9 Primaxin 54 65 -17 1 1 -53 53 64 -16 Zerbaxa 49 10 * 25 9 169 24 1 * Invanz 40 45 -10 (3) -86 41 48 -15 Cancidas 36 45 -19 1 * 35 45 -21 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 82 94 -12 85 90 -6 (2) 4 -166 Adempas (6) 57 63 -10 57 63 -10 Virology Lagevrio 825 952 -13 632 -100 825 320 158 Isentress / Isentress HD 167 178 -7 78 72 7 89 106 -16 Neuroscience Belsomra 59 80 -27 19 22 -12 39 58 -32 Immunology Simponi 166 206 -19 166 206 -19 Remicade 44 67 -34 44 67 -34 Diabetes (7) Januvia 561 878 -36 290 407 -29 271 472 -43 Janumet 353 514 -31 97 123 -21 255 391 -35 Other Pharmaceutical (8) 685 533 29 351 206 70 336 327 3 ANIMAL HEALTH 1,230 1,261 -2 396 395 - 834 866 -4 Livestock 814 791 3 188 158 19 626 633 -1 Companion Animals 416 470 -11 208 237 -12 208 233 -10 Other Revenues (9) 420 221 90 12 74 -84 408 147 178 * 200% or greater Sum of U.S. plus international may not equal global due to rounding. Table 3a MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS FOURTH QUARTER 2022 (AMOUNTS IN MILLIONS) (UNAUDITED) (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $10 million in the fourth quarter of 2022 and $27 million in the fourth quarter of 2021. Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,554 million in the fourth quarter of 2022 and $2,715 million in the fourth quarter of 2021. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $1,012 million in the fourth quarter of 2022 and $1,475 million in the fourth quarter of 2021. (8) Includes Pharmaceutical products not individually shown above. 6 -- 7 of 10 -- Full Year 2022 Full Year 2021 % Change Full Year 2022 Full Year 2021 % Change Full Year 2022 Full Year 2021 % Change TOTAL SALES (1) $59,283 $48,704 22 $27,206 $22,425 21 $32,077 $26,279 22 PHARMACEUTICAL 52,005 42,754 22 24,989 20,401 22 27,016 22,353 21 Oncology Keytruda 20,937 17,186 22 12,686 9,765 30 8,251 7,421 11 Alliance Revenue - Lynparza (2) 1,116 989 13 584 515 13 532 473 12 Alliance Revenue - Lenvima (2) 876 704 24 579 417 39 297 287 3 Alliance Revenue - Reblozyl (3) 166 17 * 123 100 43 17 153 Vaccines (4) Gardasil / Gardasil 9 6,897 5,673 22 2,065 1,881 10 4,832 3,792 27 ProQuad / M-M-R II / Varivax 2,241 2,135 5 1,724 1,629 6 518 506 2 RotaTeq 783 807 -3 508 473 8 275 334 -18 Pneumovax 23 602 893 -33 346 547 -37 256 346 -26 Vaqta 173 179 -3 95 100 -4 78 79 -2 Hospital Acute Care Bridion 1,685 1,532 10 922 762 21 762 770 -1 Prevymis 428 370 16 188 153 23 240 218 10 Dificid 263 175 50 241 166 45 22 10 130 Primaxin 239 259 -8 1 2 -9 238 258 -8 Noxafil 238 259 -8 51 60 -14 187 199 -6 Invanz 189 202 -7 4 (5) -171 185 207 -11 Cancidas 174 212 -18 6 4 51 168 208 -19 Zerbaxa 169 (1) * 89 4 * 79 (5) * Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 341 342 - 329 312 5 12 30 -62 Adempas (6) 238 252 -6 238 252 -6 Virology Lagevrio 5,684 952 * 1,523 632 141 4,161 320 * Isentress / Isentress HD 633 769 -18 274 294 -7 359 474 -24 Neuroscience Belsomra 258 318 -19 79 78 2 179 241 -26 Immunology Simponi 706 825 -14 706 825 -14 Remicade 207 299 -31 207 299 -31 Diabetes (7) Januvia 2,813 3,324 -15 1,248 1,404 -11 1,565 1,920 -18 Janumet 1,700 1,964 -13 355 367 -3 1,344 1,597 -16 Other Pharmaceutical (8) 2,249 2,118 6 969 841 15 1,282 1,275 1 ANIMAL HEALTH 5,550 5,568 - 1,822 1,758 4 3,728 3,810 -2 Livestock 3,300 3,295 - 710 667 6 2,590 2,628 -1 Companion Animals 2,250 2,273 -1 1,112 1,091 2 1,138 1,182 -4 Other Revenues (9) 1,728 382 * 395 266 48 1,333 116 * * 200% or greater Sum of U.S. plus international may not equal global due to rounding. Table 3b MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS FULL YEAR 2022 (AMOUNTS IN MILLIONS) (UNAUDITED) (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $165 million and $218 million on a global basis for December YTD 2022 and 2021, respectively. Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment. (4) Total Vaccines sales were $11,297 million and $10,132 million on a global basis for December YTD 2022 and 2021, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $4,848 million and $5,584 million on a global basis for December YTD 2022 and 2021, respectively. (8) Includes Pharmaceutical products not individually shown above. 7 -- 8 of 10 -- % Change TOTAL PHARMACEUTICAL $14,107 $12,756 $12,963 $12,180 $52,005 $9,238 $9,980 $11,496 $12,039 $42,754 1 22 United States 6,773 5,726 6,620 5,871 24,989 4,294 4,647 5,670 5,790 20,401 1 22 % Pharmaceutical Sales 48.0% 44.9% 51.1% 48.2% 48.1% 46.5% 46.6% 49.3% 48.1% 47.7% Europe (1) 3,309 2,677 2,427 2,494 10,906 2,276 2,404 2,445 2,655 9,780 -6 12 % Pharmaceutical Sales 23.5% 21.0% 18.7% 20.5% 21.0% 24.6% 24.1% 21.3% 22.1% 22.9% China 1,113 1,355 1,419 1,216 5,102 688 944 1,278 1,352 4,262 -10 20 % Pharmaceutical Sales 7.9% 10.6% 10.9% 10.0% 9.8% 7.4% 9.5% 11.1% 11.2% 10.0% Japan 965 1,092 653 832 3,542 607 637 614 771 2,629 8 35 % Pharmaceutical Sales 6.8% 8.6% 5.0% 6.8% 6.8% 6.6% 6.4% 5.3% 6.4% 6.1% Asia Pacific (other than China and Japan) 786 854 702 691 3,034 437 442 450 488 1,817 42 67 % Pharmaceutical Sales 5.6% 6.7% 5.4% 5.7% 5.8% 4.7% 4.4% 3.9% 4.1% 4.2% Latin America 435 453 511 472 1,871 353 379 434 421 1,587 12 18 % Pharmaceutical Sales 3.1% 3.6% 3.9% 3.9% 3.6% 3.8% 3.8% 3.8% 3.5% 3.7% Eastern Europe/Middle East/Africa 450 339 360 320 1,469 357 318 362 278 1,315 15 12 % Pharmaceutical Sales 3.2% 2.7% 2.8% 2.6% 2.8% 3.9% 3.2% 3.1% 2.3% 3.1% Canada 189 166 166 158 678 160 157 164 167 650 -6 4 % Pharmaceutical Sales 1.3% 1.3% 1.3% 1.3% 1.3% 1.7% 1.6% 1.4% 1.4% 1.5% Other 87 94 105 126 414 66 52 79 117 313 8 32 % Pharmaceutical Sales 0.6% 0.6% 0.9% 1.0% 0.8% 0.8% 0.4% 0.8% 0.9% 0.8% 2022 2021 MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c Full Year Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 2Q 3Q 4Q Full Year 4Q 1Q 2Q 3Q 4Q Full Year 1Q 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 4Q22 4Q21 Full Year 2022 Full Year 2021 Interest income (95) $ (9) $ (157) $ (36) $ Interest expense 235 208 962 806 Exchange losses 17 95 237 297 Loss (income) from investments in equity securities, net (1) 59 (403) 1,419 (1,940) Net periodic defined benefit plan cost (credit) other than service cost (71) (53) (279) (212) Other, net (220) (171) (681) (256) Total (75) $ (333) $ 1,501 $ (1,341) $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --